Eledon Pharmaceuticals, INC 8-K filings

Eledon Pharmaceuticals reported strong Q2 2026 results, with successful FDA meetings for its Phase 3 kidney transplant trial and promising clinical data for tegoprubart.

Eledon Pharmaceuticals announced its full year 2025 financial results and significant clinical progress for its lead drug candidate, tegoprubart, across multiple transplantation programs.

Eledon Pharmaceuticals exchanged 4,203,764 common shares for pre-funded warrants with Coastlands Capital Partners LP, restructuring an existing equity position.

Eledon Pharmaceuticals announced its third quarter 2025 financial results and positive Phase 2 BESTOW trial data for tegoprubart, supporting its advancement into Phase 3 development for kidney transplant rejection prevention.

Eledon Pharmaceuticals, Inc. announced an underwritten public offering of common stock and pre-funded warrants, aiming to raise approximately $46.5 million for clinical development and general corporate purposes.

Eledon Pharmaceuticals announced positive Phase 2 trial results for tegoprubart in kidney transplant rejection prevention, highlighting a favorable safety profile and plans for Phase 3 development, alongside a preliminary cash balance of $93.4 million.

Eledon Pharmaceuticals reported its second quarter 2025 operating and financial results, highlighted positive clinical data for tegoprubart, and announced a restatement of previously issued financial statements due to an accounting error.

Eledon Pharmaceuticals announced updated Phase 1b data for tegoprubart, showing superior kidney function and graft survival predictions compared to standard of care in transplant patients.

Eledon Pharmaceuticals, Inc. announced that its stockholders approved an increase in authorized common stock and extended exculpation protection to officers, alongside re-electing directors and ratifying auditors at its Annual Meeting.

Eledon Pharmaceuticals announces its first quarter 2025 financial results, highlighting progress in tegoprubart trials and its role in kidney transplantation.

Eledon Pharmaceuticals amends its previous 8-K filing to correct a reference to Crowe LLP regarding the fiscal year ended December 31, 2023.

Eledon Pharmaceuticals has dismissed Crowe LLP as its independent auditor and appointed Deloitte & Touche LLP, effective April 1, 2025.

Eledon Pharmaceuticals announces positive clinical data, financial results for 2024, and an extended cash runway through 2026, driven by a successful $85 million offering.

Eledon Pharmaceuticals has modified its CEO's performance bonus agreement, increasing the potential maximum payout based on the company's market value.

Eledon Pharmaceuticals reports positive clinical trial updates, including accelerated enrollment in a kidney transplant trial and promising initial data in type 1 diabetes, alongside a successful $85 million capital raise.

Eledon Pharmaceuticals has announced the pricing of an $85 million underwritten public offering of common stock and pre-funded warrants.

Eledon Pharmaceuticals reports promising initial data from a trial using tegoprubart in islet transplantation for type 1 diabetes, with two of three patients achieving insulin independence.

Eledon Pharmaceuticals has finalized the sale of 1,727,400 shares of common stock, generating approximately $4 million in gross proceeds.

Eledon Pharmaceuticals has entered into an agreement with Guggenheim Securities to sell up to $75 million of its common stock through an at-the-market offering.

Eledon Pharmaceuticals reported positive progress in its clinical trials and secured $50 million in funding, but also announced a restatement of prior financial statements due to an accounting reclassification of warrants.

Eledon Pharmaceuticals has changed its independent registered public accounting firm from KMJ Corbin & Company LLP to Crowe LLP, effective July 10, 2024.

Eledon Pharmaceuticals has finalized the sale of 909,088 shares of common stock, generating approximately $2.1 million in gross proceeds.

Eledon Pharmaceuticals' stockholders approved an increase in the share limit for the 2020 Long Term Incentive Plan and elected two Class I Directors at the annual meeting on July 10, 2024.

Eledon Pharmaceuticals announced its first quarter 2024 financial results, highlighted by a $50 million private placement and progress in clinical trials for tegoprubart.

Eledon Pharmaceuticals has successfully completed a $50 million private placement and announced positive clinical trial updates for its lead drug candidate, tegoprubart.

Eledon Pharmaceuticals announced positive clinical trial results for its lead drug candidate, tegoprubart, and a significant reduction in net loss for 2023.